$129 Million

Inozyme Pharma

Initial Public Offering

Bookrunner, July 2020

Inozyme Pharma, Inc. is a rare disease company focused on the development of novel therapeutics for the treatment of diseases and disorders of mineralization impacting the vasculature, soft tissue and skeleton. The Company’s lead product candidate, INZ-701, is a recombinant soluble fusion protein. INZ-701 is designed to modify a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies that is central to the regulation of calcium deposition throughout the body and is further associated with neointimal proliferation, or the narrowing of blood vessels caused by ingrowth of smooth muscle cells.

More Like This

Jul 2020
$288 Million

Initial Public Offering

Bookrunner

View Details
Jul 2020
$205 Million

Initial Public Offering

Bookrunner

View Details
Jul 2020
$460 Million

Initial Public Offering

Bookrunner

View Details